VesselAlert
Name: ELSBORG
MMSI: 244847000
Callsign: PBYI
Type: Cargo
Flag: Netherlands
Seen: 08-Mar-2026 13:42:11 CET
Speed: 10.3 kts
Heading: 16 deg
Dest.: VEJLE
Distance: 48.1 nm
Signal RSSI: 0.0 dBFS
Ship AIS VesselAlert © kx1t - link

VesselAlert
Name: ELSBORG
MMSI: 244847000
Callsign: PBYI
Type: Cargo
Flag: Netherlands
Seen: 06-Mar-2026 22:27:14 CET
Speed: 0.0 kts
Heading: 83 deg
Dest.: IJMUIDEN
Distance: 63.4 nm
Signal RSSI: 0.0 dBFS
Ship AIS VesselAlert © kx1t - link

Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results Puma Biotechnology (NASDAQ: PBYI) reported fourth quarter and full year 2025 results. Full-year product revenue was $204.1M and total revenue was $228.4M. GAAP net income for 2025 was $31.1M ($0.61 diluted). Cash, equivalents, and marketable securities totaled $97.5M; total debt fell to $22.5M. Puma provided 2026 guidance: total revenue $214–$221M and net income $10–$13M. Management highlighted continued profitability and upcoming alisertib clinical data presentations in 2026.

#PBYI Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/PBYI/puma-biotechno...

New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand Puma Biotechnology (NASDAQ: PBYI) licensed NERLYNX® (neratinib) is now available in Thailand via Specialised Therapeutics following Thai FDA approval in December 2024.NERLYNX is approved as a single agent for extended adjuvant treatment of early-stage HR+ HER2+ breast cancer within 12 months of completing trastuzumab, and with capecitabine for advanced/metastatic HER2+ disease after two or more prior anti-HER2 regimens.Clinical data cited include a reduction in five-year recurrence risk by up to 42% in early-stage HR+ patients and, in advanced disease, a 2.2-month mean PFS improvement and longer response duration (8.5 vs 5.6 months) with NERLYNX+capecitabine versus lapatinib+capecitabine.

#PBYI New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand

www.stocktitan.net/news/PBYI/new-breast-can...

Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI) Puma Biotechnology (NASDAQ: PBYI) was added to the Nasdaq Biotechnology Index (NBI) effective at the close of trading on December 19, 2025. The company said inclusion recognizes its commercial execution, profitability, and clinical progress, citing sustained demand for NERLYNX and advancing development of alisertib. The NBI tracks securities classified as biotechnology or pharmaceutical and requires eligibility criteria such as minimum market capitalization, average daily trading volume, and public company seasoning. The index is reviewed annually each December and is calculated using a modified capitalization-weighted methodology. Inclusion is intended to enhance visibility within the biotechnology investment community.

#NBI #PBYI Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)

www.stocktitan.net/news/NBI/puma-biotechnol...

#PBYI Puma Biotechnology Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/PBYI/puma-biotechno...

Small-cap stocks in new downtrend with AROON Oscillator, Tue Jul 29th - #PBYI #QDEL #REAX #SEAT #SPWR #TBLA #XPEL #DOGZ #ECPG #FCEL #GEOS #HLIT #IDN #JAMF #KE #MITK #NEO #CRMT #BNRG #ADEA #ZIP #XPER #ONTF #HIPO - More: crystalequityresearch.com/leading-indi... - #smallcap

Puma Biotechnology Reports First Quarter Financial Results Puma Biotechnology (NASDAQ: PBYI) reported strong Q1 2025 financial results, with net product revenue of $43.1 million from NERLYNX sales, up from $40.3 million in Q1 2024. The company achieved net income of $3.0 million ($0.06 per share), compared to a net loss of $4.8 million in Q1 2024. Total revenue reached $46.0 million, including $2.9 million in royalty revenue. Operating costs decreased to $42.0 million from $46.1 million year-over-year. The company maintains a strong cash position of $93.2 million. Looking ahead, Puma expects Q2 2025 net product revenue of $48-50 million and full-year 2025 net product revenue of $192-198 million, with projected net income of $23-28 million for the year.

#PBYI Puma Biotechnology Reports First Quarter Financial Results

www.stocktitan.net/news/PBYI/puma-biotechno...

New Clinical Data: Puma's Cancer Drug Combo Shows 75% Response Rate in Hard-to-Treat Tumors Phase I trial reveals promising efficacy of neratinib-trastuzumab combo in pancreatic cancer, with 3 of 5 patients showing tumor regression. See full results.

#PBYI #AZN Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025

www.stocktitan.net/news/PBYI/puma-biotechno...

Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results Puma Biotechnology (NASDAQ: PBYI) reported its Q4 and full-year 2024 financial results, showing mixed performance. Q4 2024 product revenue from NERLYNX® sales increased to $54.4M from $53.2M in Q4 2023, while full-year product revenue decreased to $195.2M from $203.1M in 2023.The company achieved Q4 2024 net income of $19.3M ($0.39 per share), up from $12.3M ($0.26 per share) in Q4 2023. Full-year net income rose to $30.3M ($0.62 per share) from $21.6M in 2023. The Q4 results include a $7.1M benefit from a partial release of valuation allowance.Cash position strengthened to $101M by December 31, 2024, compared to $96M year-over-year. The company initiated the ALISCA™-Breast1 Phase II trial for alisertib in November and anticipates key clinical milestones throughout 2025.

#PBYI Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/PBYI/puma-biotechno...

🏥 Puma Biotech Q1 2024: Adj. loss 5c/share, narrower than Zacks estimate of -16c. YoY improvement! 🚀 #BioTech #PBYI https://fefd.link/oyP0f

Puma Biotech's NERLYNX Secures Major NCCN Guidelines Recognition for Cervical Cancer Treatment NERLYNX earns coveted NCCN guideline inclusion as second-line therapy for HER2-mutated cervical cancer, expanding treatment options for metastatic patients.

#PBYI Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

www.stocktitan.net/news/PBYI/puma-biotechno...

#PBYI Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

www.stocktitan.net/news/PBYI/puma-biotechno...